Priaxon AG i.L., based in Munich, Germany, discovers and develops small molecule therapeutics for novel target-ligand interactions. Proprietary, highly versatile chemo-informatics tools rapidly identify essential molecular determinants of novel target-ligand interactions, and apply this information to select suitable ligand motifs in previously unexplored chemical space.

Our company goal is to demonstrate the superior efficiency in terms of innovation, timelines and R&D economics of applying Priaxon’s tools to the rapid evaluation and NCE based exploitation of new drug targets.

Combined, the Priaxplore® tools provide for rapid initial in silico hit prediction, reduced synthetic chemistry workload and focused hit screening campaigns of pre-optimised molecular entities with novel chemotypes. Moreover, the required input for successful application is either target structural information, or the structure of a known ligand, but not necessarily both.

Priaxons R&D approach is truly target-based, and applies similarly to novel drug targets (e.g. PPIs, epigenetic targets), and novel interaction mechanisms on established targets (e.g. allosteric control of kinase activity).

Unlike many competitors’ approaches, it is not restricted to technologies, chemical libraries or assay formats specific to a given target class. On the contrary, potential novel targets can be evaluated for their accessibility and biological impact using rapidly generated, proprietary tool compounds- as soon as structural information is available on either the target or a known modulator.

Proof of the attraction and validity of Priaxons R&D process is constituted by a 2010 early discovery collaboration/license deal with Boehringer Ingelheim on Priaxons NCE inhibitors of the mdm2/p53 interaction. An ongoing collaboration with GlaxoSmithKline (GSK) on an undisclosed ion channel PPI target of relevance in CV indications underscores continued Industry interest.